Pacific Biomarkers, Inc. Awarded Nine Contracts in Early 2011 for Studies in Immunogenicity, Diabetes and Other Areas

SEATTLE, WA--(Marketwire - April 26, 2011) - Pacific Biomarkers, Inc. (PBI) (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has been awarded by one sponsor, nine contracts in early 2011 with a total value of approximately $920,000. The nine contracts are in the areas of immunogenicity, tech transfers, diabetes, ADA, inflammatory and bone markers. The work will take place in FY2011 to FY2014.

Sheri’ DuMond, PBI’s Director of Business Development, said, “These contracts are evidence of the importance and relevance of PBI’s services to the pharmaceutical and biotech research community. They show that our expertise is a valuable asset, and position us for further growth as we seek to expand our market presence.”

About Pacific Biomarkers, Inc. (PBI)
Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, mass spectrometry, and multiplex testing. PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC.”

For more information about PBI, visit the company’s website at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company’s biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2010).